Reviewed by WANGYATAO·Last reviewed 2026-11-11·Medical disclaimer

In short

DILI mimics every other liver disease and has no single diagnostic test. The Chinese primary care guideline sets out how it is recognised, which drugs are most often responsible in China, and how causality is scored.

What this guide covers: Why it is hard · What causes it in China · Patterns of injury · Establishing the diagnosis · Management

Drug-induced liver injury — DILI — is liver damage caused by a medicine, a biologic, a herbal preparation, a dietary supplement, or their metabolites or contaminants. It is uncommon in absolute terms but common enough that any clinician who prescribes will meet it, and it is a leading cause of acute liver failure referrals in many settings.

The Chinese guideline for DILI in primary care, developed under the Chinese Medical Association with the hepatology drug-induced liver disease study group and general practice representation, is aimed at the front line: how to suspect it, how to establish the diagnosis, how to predict severity, and how to manage follow-up.

Why it is hard

There is no specific biomarker. DILI can look like viral hepatitis, autoimmune hepatitis, biliary obstruction or fatty liver disease, and the diagnosis is one of exclusion combined with a careful timeline. Because there is no confirmatory test, the guideline places heavy weight on structured causality assessment rather than clinical impression.

What causes it in China

The range of implicated agents is broader than in Western series. Prescription medicines are the usual suspects — antibiotics, non-steroidal anti-inflammatory drugs, statins, antituberculosis drugs, antineoplastic and immunomodulating agents — but Chinese case series consistently identify traditional Chinese medicines and dietary supplements as a large share of cases, in some cohorts the single largest category. That matters clinically: patients frequently do not volunteer herbal or supplement use unless asked directly.

Patterns of injury

DILI is classified by the pattern of enzyme elevation. Hepatocellular injury shows a dominant rise in alanine aminotransferase. Cholestatic injury shows a dominant rise in alkaline phosphatase with or without bilirubin. Mixed injury falls between the two. The pattern helps narrow the culprit list and has prognostic significance — jaundice with hepatocellular injury carries the worst prognosis.

Establishing the diagnosis

The workup has three parts. First, a detailed drug history including start dates, dose changes, over-the-counter medicines, herbal products and supplements, because the latency between starting a drug and injury is the single most informative clue. Second, exclusion of alternative causes: viral hepatitis serology, autoimmune markers, imaging of the biliary tree, and assessment for alcohol and metabolic fatty liver disease. Third, structured causality scoring, which weighs the temporal relationship, the pattern of injury, exclusion of other causes, previous reports of the drug causing liver injury, and the response to withdrawal.

Management

The core intervention is stopping the suspected agent. Most patients improve once the drug is withdrawn, and the guideline emphasises that early recognition and withdrawal is the main determinant of outcome. Supportive care and monitoring follow; specific therapy is limited, though the guideline discusses the role of hepatoprotective agents and corticosteroids in selected immune-mediated presentations.

Severity is assessed by bilirubin, transaminase level, coagulopathy and the presence of symptoms, and patients meeting criteria for severe injury are referred rather than managed in primary care.

Follow-up and prevention

Liver tests are repeated after withdrawal to document recovery, and the culprit drug is recorded permanently in the patient's record. Recurrence on re-exposure is well described, so rechallenge is avoided. Prevention is largely informational: patients starting medicines with known hepatotoxic potential should know which symptoms — jaundice, dark urine, unusual fatigue, right upper quadrant discomfort — warrant an urgent liver test rather than waiting for the next scheduled visit.

Sources and further reading

One reference to a U.S. government health source (National Institutes of Health or MedlinePlus) for the medical background of this guide. It is context, not a substitute for advice from your treating doctor.

General information for international patients, not medical advice or a diagnosis. Read the medical disclaimer.